美国 · 财经报刊 · Investor's Business Daily
How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs
Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots The post How Halozyme, Up 80% This Year,…
在 Investor's Business Daily 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.investors.com)
